Center for Substance Abuse Treatment. 2008. Managing depressive symptoms in substance abuse clients during early recovery. Treatment Improvement Protocol (TIP) Series, No. 48: Appendix D—DSM-IV-TR Mood Disorders. Available from: http://www.ncbi.nlm.nih.gov/books/NBK64063/. The reason I chose this source is because I wanted readers to be able to link to the DSM and see how MDD is categorized. Without this, readers might not know how it is categorized.
Cubala WJ, Landowski J. 2014. Low baseline salivary alpha-amylase in drug-naive paitents with short-illness-duration first episode major depressive disorder. Jorunal of Affective Disorders. 157(20):14-17. Available from: http://www.sciencedirect.com/science/article/pii/S0165032713008963. This source allows the reader to see that work towards a metabolic assay is being conducted, although it is in its very early phases and needs to have more conclusive data to be considered a great assay.
Duncan J, Johnson S, Ou XM. 2012. Monoamine oxidases in major depressive disorder and alcoholism. Drug Discov Ther. 6(3):112-22. Available from: http://www.ddtjournal.com/action/downloaddoc.php?docid=559. This article is the crème de la crème for wanting to show the effects of monoamine oxidase (MAO) on major depressive disorder. Duncan et al. (2012) are able to show the correlation between MAOs and subsequently produced neurotransmitters that have been documented in major depressive disorder. Not only MAOs, but the work extends to show transcription factors that also affect these MAOs, giving a lot of enzymatic explanation for this disorder. I am also a fan of correlating stress and MAOs (in my case I feel anxiety and depression go hand in hand). This article can help explain what MAOs are doing in a neuroscience-esque environment.
Finberg JPM. 2014. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release. Pharmacology and Therapeutics. Available from: http://www.sciencedirect.com/science/article/pii/S0163725814000497. I wanted to include this article because it talks about the use of MAOIs in a modern context. Most of the research and use of MAOIs is old, and with the Goldstein et al. (2014) paper I wanted a fresh look at MAOIs.
Freis ED. 1954. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. New England Journal of Medicine. 251:1006-1008. Available from: http://profiles.nlm.nih.gov/ps/access/XFBBGX.pdf. This article was chosen because it shows one of the first cases in which monoamine degradation is responsible for depression. This work had sparked the work of almost all other MAO based works.
Goldberg JS, Bell CE Jr, Pollard DA. 2014. Revisiting the monoamine hypothesis of depression: a new perspective. Perspect Medicin Chem. 6:1-8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981571/. The reason that I want to include this article is because I had almost completely forgotten about GABA and I wanted to look into research about GABA and Major Depressive Disorder. Although this article is not specific about MDD, it does show that MAO is also involved in the degradation of GABA, so that might be a factor that I might not have considered.
Grunewald M, Johnson S, Lu D, Wang Z, Lomberk G, Albert PA, Stockmeier CA, Meyer JH, Urrutia R, Miczek KA, Austin MC, Wang J, Paul IA, Woolverton WL, Seo S, Sittman DB, OU XM. 2012. Mechanistic role for a novel glucocorticoid-KLF11 (TIEG2) protein pathway in stress-induced monoamine oxidase a expression. Journal of Biological Chemisty. 287:24195-24206. Available from: http://www.jbc.org/content/287/29/24195.long. This article was a JBC article that talked about WHY there might be more MAO-A, so of course I included it! I wish I had found this for the spotlight #4, but now my readers get to see some good science about how KLF11 upregulates MAO-A in a human model.
Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L. 2012. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 40(7):1357-65. Available from: http://dmd.aspetjournals.org/content/40/7/1357.long. I wanted to include a clinical research article (hoping I get this new job) but also to show how treatment of major depressive disorder is done using novel antidepressants. I chose this study because they were able to isolate CYP2A6 and CYP2B6 as causal agents are suspected to metabolize the drug. This correlates to other sources that talk about how monoamine oxidases such as CYP2B6 are involved in major depressive disorder. Being able to show more fine details about Km and Vmax of these enzymes with this drug would also show how biochemical analysis is still relevant (especially relevant) when looking at how drugs affect an enzyme.
Johnson S, Stockmeier CA, Meyer JH, Austin MC, Albert PR, Wang J, May WL, Rajkowska G, Overholser JC, Jurjus G, Johnson C, Sittman DB, Ou XM. 2011. The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology. 36(10):2139-48. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158311/. This article could be a segway article between treatment and causation of the disease. A lot of the work with MAO-A fits in with work in other articles being used for this project. I was a fan of the authors’ use of western blot to show a quick point that MAO A levels are higher for major depressive disorder. I also found a historical article about MAO A from this paper that has been useful in writing an introduction. I feel thought that this paper lacks some of the fine experiments of enzyme activity in other papers presented.
Ma J, Yoshimura M, Yamashita E, Nakagawa A, Ito A, Tsukihara T. 2004. Strucutre of rat monoamine oxidase a and its specific recognitions for substrates and inhibitors. Journal of Molecular Biology. 338(1):103-114. Available from: http://www.sciencedirect.com/science/article/pii/S0022283604001998. This is the only crystal structure of MAO-A that I have been able to find. I hope that there is more work with this in the future, as this is the only structural data I have to present to the reader.
http://www.mayoclinic.org/diseases-conditions/depression/basics/definition/con-20032977. I needed a definition of depression to base my definition off of, so here is the web page I used to help create the definition.
http://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983. This page was used to help determine a definition of tricyclics in terms of what kind of drug they were.
http://www.nimh.nih.gov/health/topics/depression/index.shtml?utm_source=BrainLine.orgutm_medium=Twitter. I used this page in conjunction to the MAYO Clinic page to create a definition of MDD.
Peng YL, Liu YN, Liu L, Wang X, Jiang CL, Wang YX. 2012. Inducible nitric oxide synthase is involved in the modulation of depressive behaviors induced by unpredictable chronic mild stress. J. Neuroinflammation. 9:75. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390904/. I wanted to investigate the effect of other neurotransmitters in this disease beside just dopamine (as mention in other articles). By looking at iNOS this is a good correlation between major depressive disorder and anxiety. I feel that this article will help to show that there are other factors associated in major depressive disorder besides MAO and dopamine.
Schildkraut JJ, Kety SS. 1967. Biogenic amines and emotion. Science. 156(3771):21-30. Available from: http://www.sciencemag.org/content/156/3771/21.long. This article is a science article from the 60’s that is one of the first to show that monoamines are related to MDD…how cool is that! Great history for the reader in my opinion.
Shyn SI, Hamilton SP. 2010. The genetics of major depression: moving beyond the monoamine hypothesis. Psychiartr Clin North Am. 33(1):125-40. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0193-953X(09)00098-7. This article will be included to suggest branching out future research from just MAO A, as it seems to be the dominating theory in the field at the moment. I want to show the reader that there are other options to consider although MAOs are one of the most commonly understood methods at the moment.
Takahashi S. 1977. Monoamine oxidase activity in blood platelets from amnic and dpressed patients. Folia Psychiatr Neurol Jpn. 31(1):37-48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/863345. Although I need to take out an interlibrary loan, I believe that this article is relevant to setting up a historical context for this website. It has been known since the late 70’s that there was something going on with MAO A and major depressive disorder, so I want to know what this work revealed and why research only resumed 20 years later. I feel that the historical story will be worthwhile to investigate.
Yukozimo. 2014. Who discovered depression. Available from: http://discovery.yukozimo.com/who-discovered-depression/. This source does a good job at giving a general overview of the history of MDD. It also allowed me to find some other sources throughout my work.
Zimmerman F. 1995. The history of melancholy. The Journal of the International Insititue. 2(2). Available from: http://quod.lib.umich.edu/j/jii/4750978.0002.205/–history-of-melancholy?rgn=main;view=fulltext. This source was chosen to show a historical context of MDD. Finding a source as far back as ancient greece was cool, and I thought it enriched the history.